• Avergen Pharmaceuticals GmbH
  • Am Klopferspitz 19
  • 82152 Planegg/Martinsried
  • Germany
  • Phone: +49 (0)89/23 51 33 67
  • moc.negreva@ofni

Dr. Marius Yildiz, Geschäftsführer / Managing Director

About Avergen

We are dedicated to push the boundaries of medical research and find breakthrough therapies for neurodegenerative diseases. Avergen Pharmaceutical GmbH (APG) located in Munich, Germany creates long-term value through collaborative innovative drug discovery programs based on novel drug targets. APG is focused on its core competence in neurodegenerative diseases up to phase II clinical studies. We have an ongoing very successful research cooperation with the University of Munich. All steps involving technology outside the competency of Avergen are outsourced. A complete vertical integration is not planned. Thus, we are looking for industry partners to market our drug candidates.

What is your motivation?

We are developing new treatments for neurodegenerative diseases. Our first drug discovery program is focused on Huntington’s disease (HD). There are 600,000 individuals at risk to develop HD and 90,000 patients with HD in North America and Europe combined. Patients with HD show predominantly central nervous system (CNS) manifestations, including involuntary movements, cognitive decline and personality changes. HD leads to considerable disability and, eventually every person affected by HD will lose the ability to live independently and die. No disease modifying therapies are available for HD. APG has identified a new way of reducing aggregation of mutated huntingtin. The drug candidate is a small molecule, which may be applied orally. Recently, we could demonstrate that our lead compound improves significantly motor symptoms in a rodent model of Huntington’s disease.

“The location of the company at the IZB enables us to extend our network and profit from flexible opportunities to grow our business.”

Dr. Marius Yildiz, Geschäftsführer / Managing Director

Avergen Pharmaceutical GmbH (APG) was founded 2015 in Munich, Germany. APG is dedicated on innovative novel drug targets in its core competence area in CNS diseases. APG is focusing on the development of new drug candidates until phase II clinical studies. Academic and biotech collaborations will assist APG in its early stage drug discovery activities. APG’s long term objective is to enter into licensing agreements with major biotech or pharmaceutical companies and to clinically develop, manufacture and market its key assets. A complete vertical integration of the value chain is not planned.